Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Change in Inventory (2022 - 2025)

Historic Change in Inventory for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $5.0 million.

  • Axsome Therapeutics' Change in Inventory rose 48773.29% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year increase of 17028.19%. This contributed to the annual value of -$744000.0 for FY2024, which is 10912.21% down from last year.
  • Per Axsome Therapeutics' latest filing, its Change in Inventory stood at $5.0 million for Q3 2025, which was up 48773.29% from $1.8 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Change in Inventory ranged from a high of $5.0 million in Q3 2025 and a low of -$1.7 million during Q3 2023
  • For the 4-year period, Axsome Therapeutics' Change in Inventory averaged around $1.2 million, with its median value being $1.1 million (2024).
  • Its Change in Inventory has fluctuated over the past 5 years, first crashed by 68181.82% in 2023, then soared by 48773.29% in 2025.
  • Axsome Therapeutics' Change in Inventory (Quarter) stood at $1.3 million in 2022, then surged by 269.74% to $4.9 million in 2023, then crashed by 76.9% to $1.1 million in 2024, then soared by 342.34% to $5.0 million in 2025.
  • Its Change in Inventory stands at $5.0 million for Q3 2025, versus $1.8 million for Q2 2025 and $249000.0 for Q1 2025.